Alkermes (NASDAQ:ALKS) Issues FY 2026 Earnings Guidance

Alkermes (NASDAQ:ALKS) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of -0.521–0.405 for the period, compared to the consensus EPS estimate of -0.090. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion.

Alkermes Stock Performance

Shares of NASDAQ ALKS traded up $1.34 during midday trading on Tuesday, hitting $35.51. 1,322,971 shares of the company’s stock traded hands, compared to its average volume of 2,230,900. Alkermes has a 1 year low of $25.17 and a 1 year high of $36.48. The stock has a market capitalization of $5.90 billion, a price-to-earnings ratio of 24.79 and a beta of 0.31. The firm has a fifty day moving average of $31.44 and a 200 day moving average of $30.95.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Saturday, February 14th. The company reported $0.29 earnings per share (EPS) for the quarter. The company had revenue of $384.55 million for the quarter. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. On average, equities analysts anticipate that Alkermes will post -0.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Truist Financial upgraded Alkermes to a “strong-buy” rating in a research note on Wednesday, March 25th. Zacks Research raised Alkermes from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen downgraded Alkermes from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Piper Sandler decreased their target price on shares of Alkermes from $45.00 to $43.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 24th. Finally, Wells Fargo & Company upped their price target on shares of Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $44.29.

Insider Buying and Selling

In other Alkermes news, EVP David Joseph Gaffin sold 2,034 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $33.20, for a total value of $67,528.80. Following the completion of the transaction, the executive vice president directly owned 231,558 shares in the company, valued at $7,687,725.60. This represents a 0.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christian Todd Nichols sold 6,000 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $30.00, for a total transaction of $180,000.00. Following the sale, the senior vice president directly owned 109,769 shares of the company’s stock, valued at approximately $3,293,070. This trade represents a 5.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 39,102 shares of company stock valued at $1,265,090. Corporate insiders own 4.59% of the company’s stock.

Hedge Funds Weigh In On Alkermes

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALKS. T. Rowe Price Investment Management Inc. purchased a new position in Alkermes during the 4th quarter valued at approximately $59,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Alkermes in the fourth quarter valued at $256,000. Summit Global Investments increased its position in Alkermes by 48.8% in the fourth quarter. Summit Global Investments now owns 29,662 shares of the company’s stock worth $830,000 after purchasing an additional 9,724 shares during the last quarter. Vident Advisory LLC increased its position in Alkermes by 1.1% in the fourth quarter. Vident Advisory LLC now owns 82,294 shares of the company’s stock worth $2,303,000 after purchasing an additional 864 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in Alkermes during the fourth quarter valued at $1,712,000. 95.21% of the stock is owned by institutional investors.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.